Category: piperazines

On February 22, 2001, Fekete, Pal; Fellner, Gyorgy, Mrs.; Gora, Laszlo, Mrs.; Jambor, Istvan, Mrs.; Feikus, Szilvia; Palfi, Zoltan, Mrs.; Zsigmond, Zsolt published a patent.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Ciprofloxacin-containing pharmaceutical composition and process for the preparation thereof. And the patent contained the following:

The invention relates to an immediate-release pharmaceutical composition containing ciprofloxacin, a binder, disintegrating agent and optionally further pharmaceutical auxiliary agents. The composition comprises 60-80 % of ciprofloxacin (in the form of ciprofloxacin hydrochloride monohydrate), 2-10 % of maltodextrin, 5-15 % of a disintegrating agent of carboxymethyl starch type, 3-6 % of silica, 1-3 % of a lubricant and optional 2-6 % of a film-coating layer for film-coated tablets. A tablet contained ciprofloxacin hydrochloride monohydrate 582, Na CM starch 82, maltodextrin 40, silica 40, Mg stearate 6, and Opadry Y-1-7000 16 mg. The tablet was dissolved in the amounts of 94.3, 95.4, and 98.5 % in 5, 15, and 30 min, resp. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to immediate release tablet ciprofloxacin, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On December 31, 2008, Pastini, Ana C.; Faour, Joaquina; Vergez, Juan A.; Ricci, Marcelo A.; Fischbein, Gustavo A. published a patent.Recommanded Product: 86393-32-0 The title of the patent was A rupturing controlled release device comprising a subcoat. And the patent contained the following:

The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Recommanded Product: 86393-32-0

The Article related to controlled release delivery rupturing, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 28, 2002, Singh, Onkar N.; Bhagat, Haresh G.; Kabra, Bhagwati P. published a patent.Category: piperazines The title of the patent was Topical composition comprising ciprofloxacin and hydrocortisone. And the patent contained the following:

This invention is directed toward a topical composition comprising ciprofloxacin and hydrocortisone, where the composition contains a specific grade of poly(vinyl alc.) as a viscosity augmenter. The specified grade of polyvinyl alc. is 85-90% hydrolyzed poly(vinyl alc.). Thus, a composition contained ciprofloxacin-HCl monohydrate 0.35, micronized hydrocortisone 1.9, benzyl alc. 0.9, NaCl 0.9, sodium acetate trihydrate 0.68, acetic acid 0.255, Phospholipon 90H 0.15, Polysorbate-20 0.10, NaOH and/or HCl to pH 4.7, and water to 100%. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Category: piperazines

The Article related to topical ciprofloxacin hydrocortisone, Pharmaceuticals: Formulation and Compounding and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 20, 1997, Canovas Soler, Pedro; Delgadillo Duarte, Joaquin; Moreno Rueda, Juan published a patent.Category: piperazines The title of the patent was Aqueous compositions containing ciprofloxacin. And the patent contained the following:

Aqueous compositions for treatment of otitis media with perforation of the tympanic membrane contain the broad-spectrum antibiotic ciprofloxacin.HCl.H2O 0.12-0.6 (equivalent to 0.1-0.5% free base), buffer (pH 4-5) 0.5-3.0, nonionic surface-active agent 0.05-0.3, thickening agent 0.5-2.0 g, and H2O to 100 mL. This solution is packaged in sterile single dosage units without preservatives. Thus, an aqueous solution was prepared containing ciprofloxacin.HCl.H2O 0.40, AcOH 0.45, NaOAc.3H2O 1.20, polysorbate 80 0.19, methylcellulose 1.15, and glycerin 1.62 weight%. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Category: piperazines

The Article related to ciprofloxacin solution otitis media, Pharmaceuticals: Formulation and Compounding and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 20, 2005, Pshenichnikov, V. G.; Frolova, L. V.; Zaripova, Z. I.; Dmitrieva, I. M.; Besh, E. A.; Mokhnacheva, E. V.; Anishchenko, S. S.; Predeina, N. I. published a patent.Category: piperazines The title of the patent was Eye drops and method for obtaining them. And the patent contained the following:

The present innovation deals with medicinal preparations designed as solution and indicated for therapeutic needs. Eye drops contain ciprofloxacin hydrochloride monohydrate equivalent to 0.3% free base, a buffer system that keeps pH within 3.5-5.5 interval, as a conserving agent – benzalkonium chloride and as a stabilizer – the salt of disodium ethylenediamine tetraacetic acid; moreover, their range of osmolality values correspond to 150-450 mM/kg H2O. Eye drops should be obtained by preparing a buffer system in which mannitol should be dissolved followed by the salt of disodium ethylenediamine tetraacetic acid, benzalkonium chloride, and ciprofloxacin hydrochloride. Then one should perform the control for the quality of the obtained solution, which then is filtered by applying sterilizing elements and packed. This innovation provides treatment of eyes at certain desired osmolality. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Category: piperazines

The Article related to eye drop ciprofloxacin formulation, Pharmaceuticals: Formulation and Compounding and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Deka, Nabajyoti; Bajare, Swapnil; Anthony, Jessy; Nair, Amrutha; Damre, Anagha; Patel, Dharmeshkumar; B.-Rao, Chandrika; Sivaramakrishnan, H.; Mutt, Shivaprakash Jagalur; Wilankar, Chandan; Marita, Rosalind published an article in 2013, the title of the article was Synthesis of N-(6-(4-(piperazin-1-yl)phenoxy)pyridin-3-yl)benzenesulfonamide derivatives for the treatment of metabolic syndrome.Recommanded Product: 67914-60-7 And the article contains the following content:

Metabolic syndrome is a widely prevalent multifactorial disorder associated with an increased risk of cardiovascular disease and type 2 diabetes mellitus. High plasma levels of insulin and glucose due to insulin resistance are a major component of the metabolic disorder. Thiazolidinediones (TZDs) are potent PPARγ ligands and used as insulin sensitizers in the treatment of type 2 diabetes mellitus. They are potent insulin-sensitizing agents but due to adverse effects like hepatotoxicity, a safer alternative of TZDs is highly demanded. The synthesis of N-(6-(4-(piperazin-1-yl)phenoxy)pyridin-3-yl)benzenesulfonamide derivatives I (R = 2,4-Cl2C6H3, 2,5-(OCH3)2C6H3, 2-thienyl, etc.) an alternate remedy for insulin resistance is reported. The experimental process involved the reaction of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone(cas: 67914-60-7).Recommanded Product: 67914-60-7

The Article related to piperazinyl pyridinyl benzenesulfonamide preparation metabolic syndrome, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Recommanded Product: 67914-60-7

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2002, Wang, Jingkang; Liu, Yong; Yin, Qiuxiang published an article.Formula: C17H21ClFN3O4 The title of the article was Studies on the mechanism of primary nucleation of ciprofloxacin hydrochloride monohydrate. And the article contained the following:

A general expression for the relation between induction period and supersaturation was developed based on polynuclear approach. Different mechanism of primary nucleation in solution can be illustrated by the expression. The results of induction period determined by laser scattering method shows that the crystallization of ciprofloxacin hydrochloride monohydrate in water/ethanol or aqueous solution is by the mechanism of primary nucleation followed by one-dimensional diffusion growth, and then one-dimensional continuous or “birth and spread” growth on crystal face. The growth mechanism on the crystal face is affected by temperature and solvent. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Formula: C17H21ClFN3O4

The Article related to ciprofloxacin hydrochloride monohydrate primary nucleation mechanism, Unit Operations and Processes: Separation Processes and other aspects.Formula: C17H21ClFN3O4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 27, 2022, Lee, Song Hee; Ryu, Je Ho; Ahn, Jung Min; Choi, Yu Ri; Lee, Ho Hyun; Jang, Mi Young; Woo, Yae Jin; Kim, Hanwool; Kim, Ji Young; Park, Ji Youn published a patent.Related Products of 1211568-27-2 The title of the patent was Amide compound for androgen receptor degradation, and pharmaceutical use thereof. And the patent contained the following:

The present invention provides a compound I [R1 = H, alkyl, halogen, etc.; R2 = H, alkyl, halogen, etc.; X1, X3, X4 and X5 = independently CH or N; X2 = CR3 or N; R3 = H, alkyl, halogen, etc.; n = 0, 1, or 2; m = 0 or 1; L = -(CH2)q1-A1-(CH2)q2-B1-(CH2)q3-A2-(CH2)q4-B2-(CH2)q5-A3-(CH2)q6-B3-; A1, A2 and A3 = independently direct bond, -O-, -N(R4)-, etc.; R4 = H, alkyl or haloalkyl; B1, B2 and B3 = independently direct bond, cycloalkyl, heterocycle, etc.; q1-q6 = independently 0-6; E = Q1 or Q2; X6, X7, X8 and X9 = independently CH or N; Y = -C(R6)2-, -C(O)-, -C(R6)2-C(R6′)2-, etc.; Z = direct bond, -C(R6)2-, -O-, etc.; R5 and R5′ = independently H, alkyl, halogen, etc.; R6 and R6′ = independently H, alkyl, halogen, etc.] of a specific chem. structure, having androgen receptor (AR) degradation activity, or a pharmaceutically acceptable salt thereof. The present invention also provides a composition containing the compound or a pharmaceutically acceptable salt thereof. According to present invention, provided is a pharmaceutical use of the compound, the salt thereof, and the composition containing same for treating or preventing AR-related diseases. According to the present invention, further provided is a method for treating or preventing AR-related diseases, the method comprising administering, to a subject in need of treatment, an effective amount of the compound, the salt thereof, or the composition containing same. For example, compound II (preparation given) was coupled with compound III (preparation given) to provide compound IV. The experimental process involved the reaction of tert-Butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate(cas: 1211568-27-2).Related Products of 1211568-27-2

The Article related to amide compound preparation androgen receptor degradation activity, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Related Products of 1211568-27-2

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 11, 1998, De Laszlo, Stephen E.; Liverton, Nigel J.; Ponticello, Gerald S.; Selnick, Harold G.; Mantlo, Nathan B. published a patent.Electric Literature of 890092-19-0 The title of the patent was Preparation of arylpyrroles as cytokine inhibitors. And the patent contained the following:

Title compounds [I; R1 = H, alkyl, heterocyclyl, aryl, etc.; R2 = alk(en)yl, alkynyl, heterocyclyl, etc.; R3 = H, halo, alkyl, heterocyclyl, etc.; R4 = (un)substituted heteroaryl; R5 = ZR; R = 1-3 of halo, alkyl, acyl, (hetero)aryl, etc.; Z = (hetero)arylene] were prepared Thus, R5COCH2R4 (R4 = 4-pyridyl, R5 = 4-FC6H4) was α-alkylated by ClCH2COR2 (R2 = 1-benzyloxycarbonyl-4-piperidinyl)(preparation each given) and the product cyclocondensed with NH4Ac to give, after reduction, I (R1 = R3 = H, R2 = 1-methyl-4-piperidinyl, R4 = 4-pyridyl, R5 = 4-FC6H4). Data for biol. activity of I were given. The experimental process involved the reaction of 4-(4-Acetylpiperazin-1-yl)benzaldehyde(cas: 890092-19-0).Electric Literature of 890092-19-0

The Article related to arylpyrrole preparation cytokine inhibitor, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Electric Literature of 890092-19-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 16, 1986, Orjales Venero, Aurelio; Toledo Avello, Antonio published a patent.Synthetic Route of 59695-29-3 The title of the patent was Process for the preparation of amide derivatives of 4-amino-1,2,3,4,4a,9b-hexahydro-8,9b-dimethyldibenzofuran-3-one. And the patent contained the following:

The title amides I (R = alkyl; n = 1-4), known to be useful as analgesics and antitussives, are prepared by amidation of the title amine (II) with the corresponding (alkylpiperazinyl)alkanoic acids III in an anhydrous organic solvent and in the presence of a dehydrating agent. Thus, a solution of II.HCl in DMF was neutralized with K2CO3, filtered, and added to a solution of III.2HCl (R = Me, n = 2) and DCC in DMF, followed by workup and acidification, to give 50% I.2HCl (R = Me, n = 2). The experimental process involved the reaction of 3-(4-Methylpiperazin-1-yl)propanoic acid dihydrochloride(cas: 59695-29-3).Synthetic Route of 59695-29-3

The Article related to dibenzofuranone piperazinylalkanoylamino preparation analgesic antitussive, piperazinylalkanoylaminodibenzofuranone preparation analgesic antitussive, Heterocyclic Compounds (One Hetero Atom): Furans and other aspects.Synthetic Route of 59695-29-3

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics